# Bacillus coagulans Unique IS-2

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bacillus-coagulans-unique-is-2
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bacillus coagulans MTCC 5260, Bacillus coagulans ATCC PTA-11748, BC Unique IS-2, Lactobacillus sporogenes, Spore-forming lactic acid bacteria, BC IS-2, Unique IS-2 strain

## Overview

Bacillus coagulans Unique IS-2 is a spore-forming lactic acid-producing [probiotic](/ingredients/condition/gut-health) strain that survives gastric acid transit and colonizes the intestinal tract to modulate gut microbiota composition and immune signaling. Its primary mechanism involves producing L(+) lactic acid and bacteriocins that shift luminal pH, suppress pathogenic bacteria, and regulate toll-like receptor 2/4 signaling to reduce intestinal [inflammation](/ingredients/condition/inflammation).

## Health Benefits

• Significantly reduces IBS symptoms including abdominal pain (from 8.2 to 3.4 mean score), bloating, and urgency - supported by a well-designed RCT (n=108)
• Improves stool consistency and normalizes bowel movements in 65% of users versus 33% placebo - strong evidence from controlled trials
• Increases bowel movement frequency in adults with infrequent BMs (p=0.037) - moderate evidence from RCT (n=144)
• Reduces acute diarrhea duration from 35 to 3.5 minutes per day and frequency from 7.96 to 0.76 per day - preliminary evidence from open trial
• Enhances [immune function](/ingredients/condition/immune-support) with 56% of participants showing >200% increase in NK cell activity - preliminary evidence

## Mechanism of Action

Bacillus coagulans Unique IS-2 produces L(+) lactic acid and bacteriocin-like inhibitory substances (BLIS) that lower luminal pH and competitively exclude pathogens such as Clostridium difficile and Escherichia coli by disrupting their membrane integrity. The strain's spore coat proteins engage toll-like receptor 2 (TLR-2) on intestinal epithelial cells, downregulating NF-κB-mediated [pro-inflammatory cytokine](/ingredients/condition/inflammation) release, including TNF-α and IL-6, while upregulating secretory IgA production. Additionally, it produces short-chain fatty acids (SCFAs), particularly butyrate precursors, that strengthen tight-junction proteins such as occludin and claudin-1, reducing [intestinal permeability](/ingredients/condition/gut-health).

## Clinical Summary

A well-designed randomized controlled trial (RCT, n=108) demonstrated that Bacillus coagulans Unique IS-2 at 2 billion CFU/day for 90 days reduced mean abdominal pain scores from 8.2 to 3.4, compared to minimal change in placebo, with 65% of treated subjects achieving normalized stool consistency versus 33% on placebo. A secondary RCT (n=40) confirmed significant reductions in bloating, urgency, and incomplete evacuation scores over 8 weeks, with effect sizes considered clinically meaningful. Evidence quality is strong for IBS-D and IBS-M subtypes due to adequate sample sizes and blinded allocation, though long-term data beyond 90 days remains limited. Broader applicability to healthy populations for gut maintenance is supported by mechanistic data but lacks large-scale confirmatory trials.

## Nutritional Profile

Bacillus coagulans Unique IS-2 is a spore-forming probiotic bacterium, not a nutritional ingredient in the traditional macronutrient sense. As a probiotic, its 'profile' is characterized by its biological components rather than caloric or macronutrient content. Key bioactive components include: (1) Endospores — the primary delivery form, consisting of a proteinaceous spore coat (~70% protein by dry weight) with dipicolinic acid (DPA) comprising approximately 5–15% of spore dry weight, which confers heat and acid stability up to 90°C and pH 2–3 gastric conditions, enabling high viable delivery to the intestine; (2) Lactic acid — produced during vegetative growth via homofermentative pathway, contributing to gut microenvironment acidification; (3) Bacteriocins and antimicrobial peptides — short-chain proteinaceous compounds produced during colonization that competitively inhibit pathogenic bacteria; (4) Short-chain fatty acids (SCFAs) — particularly acetate and lactate, produced as metabolic byproducts during fermentation in the colon, contributing to colonocyte energy supply and [gut barrier](/ingredients/condition/gut-health) integrity; (5) Exopolysaccharides (EPS) — produced during vegetative growth, with [immunomodulatory](/ingredients/condition/immune-support) properties via TLR-2 and TLR-4 receptor interactions. Typical commercial dosage ranges from 2–6 billion CFU (colony-forming units) per serving. No significant caloric contribution (effectively 0 kcal per standard dose). No dietary fiber, fat, or micronutrient content of note in isolated form. Bioavailability advantage: spore germination rate in the small intestine is estimated at >85% under physiological conditions, significantly higher than non-spore-forming probiotics such as Lactobacillus strains, which may lose 60–80% viability through gastric transit.

## Dosage & Preparation

Clinically studied dose: 2 billion CFU/day in powder or capsule form for 4-8 weeks. This spore-forming [probiotic](/ingredients/condition/gut-health) is shelf-stable and does not require refrigeration. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bacillus coagulans Unique IS-2 is generally recognized as safe (GRAS) and well-tolerated, with transient mild bloating or flatulence reported in fewer than 5% of participants in clinical trials during the first week of use. No serious adverse events have been attributed to this strain in published human studies at doses up to 6 billion CFU/day. Caution is advised in severely immunocompromised individuals, such as those undergoing chemotherapy or with advanced HIV, as live bacterial supplementation carries a theoretical risk of bacteremia in this population. No clinically significant drug interactions have been formally documented, though concurrent use with broad-spectrum antibiotics will reduce viability of the [probiotic](/ingredients/condition/gut-health) strain and should be separated by at least 2 hours; pregnancy safety data is insufficient to make a definitive recommendation.

## Scientific Research

Clinical evidence includes multiple randomized controlled trials, notably a double-blind, placebo-controlled study in 108 IBS patients showing significant symptom reduction over 8 weeks (PMID: 31467089), and a 144-participant RCT demonstrating improved bowel movement frequency and stool consistency (PMID: 40456531, NCT05123664). Additional trials in acute diarrhea and pediatric populations support efficacy and safety, with all studies reporting good tolerability and no severe adverse events.

## Historical & Cultural Context

No historical or traditional medicine use is documented for this strain. Bacillus coagulans Unique IS-2 is a modern commercial [probiotic](/ingredients/condition/gut-health) strain (MTCC 5260) that has been studied since at least the 2010s, with no links to ancient medical systems.

## Synergistic Combinations

Prebiotic fibers, [Digestive enzyme](/ingredients/condition/gut-health)s, L-glutamine, Peppermint oil, Psyllium husk

## Frequently Asked Questions

### What is the recommended dosage of Bacillus coagulans Unique IS-2 for IBS?

Clinical trials demonstrating significant IBS symptom relief used 2 billion CFU (colony-forming units) per day of Bacillus coagulans Unique IS-2, administered once daily for 8 to 90 days. This dose produced a 58% reduction in abdominal pain scores in the key RCT (n=108) and is the most evidence-backed dosage currently available. Doses up to 6 billion CFU/day have been used in mechanistic studies without safety concerns.

### How long does Bacillus coagulans Unique IS-2 take to work?

In published RCTs, statistically significant improvements in abdominal pain and stool consistency were observed by week 4 of supplementation, with maximum benefit reported at 8 to 12 weeks. Some users report reduced bloating within the first 1 to 2 weeks as luminal pH shifts and pathogenic bacteria are suppressed by L(+) lactic acid production. Consistent daily use is required because the strain does not permanently colonize the gut and benefits diminish after discontinuation.

### Does Bacillus coagulans Unique IS-2 survive stomach acid?

Yes, Bacillus coagulans Unique IS-2 is a spore-forming bacterium whose endospores have demonstrated survival at gastric pH as low as 2.0 for up to 2 hours in in vitro challenge studies. Unlike non-spore-forming Lactobacillus species, the spore coat provides thermal and acid stability, allowing viable cells to germinate in the neutral-to-alkaline environment of the small intestine. This property makes enteric coating unnecessary, and the strain can be formulated in standard capsules or tablets without loss of efficacy.

### Is Bacillus coagulans Unique IS-2 the same as Lactobacillus sporogenes?

No, though they are frequently confused: Lactobacillus sporogenes is an outdated, taxonomically invalid name that was historically used to market spore-forming bacilli as lactobacilli to leverage consumer familiarity with Lactobacillus probiotics. Bacillus coagulans Unique IS-2 is a correctly classified, strain-specific designation under the genus Bacillus, confirmed by 16S rRNA gene sequencing, and is distinct from generic Bacillus coagulans preparations that lack strain-level identity and clinical data. Only IS-2 carries the specific clinical trial evidence described in this profile.

### Can Bacillus coagulans Unique IS-2 be taken with antibiotics?

Concurrent administration with broad-spectrum antibiotics will significantly reduce the viability of Bacillus coagulans IS-2 spores, diminishing its probiotic effect; taking the supplement at least 2 hours before or after antibiotic doses minimizes this interaction. The spore form provides some resistance compared to vegetative-state probiotics, but repeated antibiotic exposure over multiple days can still compromise colonization. Post-antibiotic use of IS-2 may help restore luminal SCFA production and competitive exclusion of opportunistic pathogens such as Clostridioides difficile, though direct evidence for this indication specifically for IS-2 is limited.

### What clinical evidence supports Bacillus coagulans Unique IS-2 for IBS symptoms?

A well-designed randomized controlled trial (n=108) demonstrated that Bacillus coagulans Unique IS-2 significantly reduced IBS abdominal pain scores from 8.2 to 3.4, along with improvements in bloating and urgency. Additionally, controlled trials show that 65% of users experienced improved stool consistency and normalized bowel movements compared to 33% in the placebo group. These results represent strong clinical evidence for IBS symptom relief, making it one of the most research-supported probiotic strains for this condition.

### Who benefits most from taking Bacillus coagulans Unique IS-2?

Bacillus coagulans Unique IS-2 is most beneficial for individuals with diagnosed IBS, particularly those experiencing abdominal pain, bloating, and irregular bowel movements. It is also effective for adults with infrequent bowel movements, as clinical evidence shows it increases bowel movement frequency (p=0.037). Those seeking to normalize stool consistency and reduce digestive urgency may see the most significant improvement with this strain.

### Can Bacillus coagulans Unique IS-2 help with constipation and infrequent bowel movements?

Yes, Bacillus coagulans Unique IS-2 has been shown to increase bowel movement frequency in adults with infrequent bowel movements based on randomized controlled trial data (p=0.037). Clinical studies also demonstrate that 65% of users experienced improved stool consistency and normalized bowel movements compared to placebo, making it effective for constipation-related issues. This makes it a suitable option for individuals seeking to restore regular and healthy bowel function.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*